NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus-Reference-Cited by-同舟云学术

NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus

Published:2014-08-14 Issue:6 Volume:136 Page:E590-E601
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Chen Ji-Li¹,Dawoodji Amina¹,Tarlton Andrea¹,Gnjatic Sacha²,Tajar Abdelouahid³,Karydis Ioannis¹,Browning Judy⁴,Pratap Sarah¹,Verfaille Christian²,Venhaus Ralph R.²,Pan Linda²,Altman Douglas G.³,Cebon Jonathan S.⁴,Old Lloyd L.²,Nathan Paul⁵,Ottensmeier Christian⁶,Middleton Mark⁷,Cerundolo Vincenzo¹

Affiliation:

1. Radcliffe Department of Medicine; MRC Human Immunology Unit; Weatherall Institute of Molecular Medicine, University of Oxford; Oxford OX3 9DU United Kingdom

2. Ludwig Institute for Cancer Research; New York NY

3. Centre for Statistics in Medicine, University of Oxford, Botnar Research Centre; Oxford OX3 7LD United Kingdom

4. Ludwig Institute for Cancer Research, Level 5, Olivia Newton-John Cancer & Wellness Centre, Austin Health; Heidelberg VIC Australia

5. Mount Vernon Cancer Centre, Mount Vernon Hospital; Northwood HA6 2RN United Kingdom

6. Southampton Experimental Cancer Medicine Centre, University Hospital Southampton NHS Foundation Trust; Southampton SO16 6YD United Kingdom

7. Oxford Cancer Centre, Churchill Hospital, Headington; Oxford OX3 7LJ United Kingdom

Funder

Cancer Research UK

Medical Research Council

Cancer vaccine Grant for Immunological Monitoring

Experimental Cancer Medical Centre

Ludwig Institute for Cancer Research

US Cancer Research Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference32 articles.

1. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara;Smith;J Immunol,2005

2. NY-ESO-1: review of an immunogenic tumor antigen;Gnjatic;Adv Cancer Res,2006

3. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients;Jager;Proc Natl Acad Sci USA,2006

4. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming;Valmori;Proc Natl Acad Sci USA,2007

5. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients;Odunsi;Proc Natl Acad Sci USA,2012

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unconventional human CD61 pairing with CD103 promotes TCR signaling and antigen-specific T cell cytotoxicity;Nature Immunology;2024-04-01

2. Adjuvant Anti-tumor Therapy with Polyphenolic Compounds: A Review;Current Medicinal Chemistry;2024-03-06

3. The quest for nanoparticle-powered vaccines in cancer immunotherapy;Journal of Nanobiotechnology;2024-02-14

4. A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma;Cancer Immunology, Immunotherapy;2023-03-07

5. Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors;eLife;2023-01-10